-Top-line results planned to be released in third quarter 2023- -Trial results are intended to support Biologics License Application (BLA) planned for fourth quarter 2023- DURHAM, N.C. , July 26, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company...
DURHAM, N.C. , June 05, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason , M.D., Ph.D.,...
- Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma - - Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access in End-Stage Renal Disease Patients - - Conference call and live webcast at 8:00 a.m. ET today - DURHAM, N.C....
- $40 million upfront, $20 million upon FDA acceptance of HAV BLA in vascular trauma, $40 million upon FDA approval of HAV in vascular trauma, $50 million upon achievement of certain sales milestones, and $10 million equity option - - Proceeds to support planned development and commercialization of...
First regenerative medicine technology used in battlefield trauma Ukrainian surgeons trained on HAV procedures over video conferencing DURHAM, N.C. , May 09, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable...
DURHAM, N.C. , May 05, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2023 , on...
HAV granted second RMAT designation by the FDA RMAT will support Humacyte’s lead indication in Vascular Trauma DURHAM, N.C. , May 04, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue...
DURHAM, N.C. , April 28, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason , M.D., Ph.D., Founder, President, and Chief...
NEW YORK, N.Y. and DURHAM, N.C. , April 27, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology company pioneering the development and manufacturing of off-the-shelf, universally implantable bioengineered human tissues and organ systems, and JDRF International (JDRF), the...
Results published in Journal of Trauma and Acute Care Surgery Company also provides update on enrollment progress in Phase 2/3 vascular trauma trial DURHAM, N.C. , April 18, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing...
